# A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer

> **NCT00915369** · PHASE1 · UNKNOWN · sponsor: **Fresenius Kabi Oncology Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Nanoxel (Paclitaxel Nanoparticle formulation )

## Key facts

- **NCT ID:** NCT00915369
- **Lead sponsor:** Fresenius Kabi Oncology Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00915369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00915369, "A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00915369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*